Preferred Label : Tilvestamab;
NCIt definition : A humanized immunoglobulin (Ig) G1 monoclonal antibody directed against AXL receptor
tyrosine kinase (AXL; UFO), with potential immunomodulating and antineoplastic activities.
Upon administration, tilvestamab targets, binds to and inhibits the activity of AXL,
which is expressed on the surfaces of a variety of cancer cell types. This prevents
AXL-mediated signaling, and may inhibit tumor cell proliferation, migration and invasion.
AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases,
is overexpressed by many tumor cell types, and plays a key role in tumor cell proliferation,
survival, invasion and metastasis; its expression is associated with drug resistance,
tumor immune evasion and poor prognosis.;
UNII : IZK2TH7X5M;
CAS number : 2226775-26-2;
Molecule name : BGB-149; BGB 149;
NCI Metathesaurus CUI : CL1413033;
Origin ID : C175866;
UMLS CUI : C5446802;
Semantic type(s)
concept_is_in_subset